Recommendations

Recommendation 1

5.6       The committee supports, in principle, the access to products derived from cannabis for use in relation to particular medical conditions where the use of those products has been proven to be safe and effective.

Recommendation 2

5.7       The committee recommends that the Bill is amended, if necessary, to establish mechanisms by which scientific evidence about medicinal cannabis products can be assessed to determine their suitability for use in the treatment of particular medical conditions.

Recommendation 3

5.10    The committee recommends that the Bill is amended to address issues raised about its interaction with the existing Commonwealth regulatory framework for medicinal products, including the Therapeutic Goods Act 1989, the Narcotics Drug Act 1967 and relevant customs legislation.

Recommendation 4

5.13    The committee recommends that the Bill is amended to ensure that medicinal cannabis products can be made available in Australia consistent with Australia's international obligations, including under Articles 23 and 28 of the Single Convention on Narcotic Drugs (1961).

Recommendation 5

5.16    The committee recommends that the Commonwealth government consult with its state and territory counterparts about the interrelationship of relevant laws to ensure a consistent approach to accessing medicinal cannabis and to facilitate compliance with any such access scheme and Australia's international obligations.

Recommendation 6

5.18    Subject to the preceding recommendations, the committee recommends that the Bill be passed.

Navigation: Previous Page | Contents | Next Page